

What is the MEVPRO-2 clinical trial?

The MEVPRO-2 clinical trial is for adults with metastatic prostate cancer.

The purpose of MEVPRO-2 is to see if taking the study medicine [(mevrometostat)] alongside a standard treatment (enzalutamide) will work better than enzalutamide alone to slow down or stop the growth of metastatic castrate-resistant prostate cancer.

How long does clinical trial participation last?



Participants will have clinic visits every 2 to 8 weeks during treatment and a follow-up 4-5 weeks after



Long-term follow-up will include visits or calls every 12 weeks



Length of participation varies based on how the cancer responds, and how well the study medicine is tolerated

All participants will be closely monitored by the study team while in the clinical trial.



 MEVPRO-2

What study treatments will participants receive?

Participants will be assigned randomly (like flipping a coin) to receive either:

- Study medicine [(mevrometostat)] **AND** enzalutamide

OR

- Placebo **AND** enzalutamide



The study medicine [(mevrometostat)] is taken as tablets by mouth twice-a-day. Enzalutamide is taken as capsules by mouth once-a-day.



A placebo looks like the study medicine, but does not contain any active ingredients.

Who can take part?

The MEVPRO-2 clinical trial may be an option for adults who have metastatic castrate-resistant prostate cancer and:



Their prostate cancer has progressed since this diagnosis



They have not started further treatments (such as chemotherapy or a different hormone therapy) since their prostate cancer was diagnosed as castrate-resistant

